Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?

This study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers will test a twice-daily dose in 50 adults who are already taking clopidogrel. The goal is to see if the higher dose provides better protection against clots without increasing bleeding risk.